Pacific Edge Ltd
NZX:PEB

Watchlist Manager
Pacific Edge Ltd Logo
Pacific Edge Ltd
NZX:PEB
Watchlist
Price: 0.13 NZD 5.69%
Market Cap: 105.5m NZD
Have any thoughts about
Pacific Edge Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-1.7
Current
-8.5
Median
4.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1.7
=
Enterprise Value
58m NZD
/
EBITDA
-33.6m NZD
All Countries
Close
Market Cap EV/EBITDA
NZ
Pacific Edge Ltd
NZX:PEB
105.5m NZD -1.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -219 659.2
US
Abbvie Inc
NYSE:ABBV
315.8B USD 15.4
US
Amgen Inc
NASDAQ:AMGN
141.1B USD 16
US
Gilead Sciences Inc
NASDAQ:GILD
117.2B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD 21.5
US
Epizyme Inc
F:EPE
94.1B EUR -514.4
AU
CSL Ltd
ASX:CSL
136.4B AUD 19.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 15.3
US
Seagen Inc
F:SGT
39.3B EUR -58.7
NL
argenx SE
XBRU:ARGX
36.2B EUR -109.9
EBITDA Growth EV/EBITDA to Growth
NZ
Pacific Edge Ltd
NZX:PEB
Average EV/EBITDA: 16.4
Negative Multiple: -1.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 659.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
5%
2.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.5
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.4 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.9 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-2.1
2-Years Forward
EV/EBITDA
-2.3
3-Years Forward
EV/EBITDA
-2.8

See Also

Discover More